Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q2 FY26 Earnings Presentation
17 slides from Ngl Fine-chem's earnings presentation, Nov 14, 2025
Slide 1: NGL Fine-Chem Limited Investor Presentation Q2 & H1FY26
NGL Fine-Chem Limited INVESTOR P R ES EN TATI ON Q2 & H1FY26
Slide 2: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 3: Inside This Presentation
Inside This Presentation Pg. No. Pg. No. 04 10 Q2 & Over view, H1FY26 Key Strengths Highlights and Strategy Pg. No. 15 Historical Financial Performance
Slide 4: Q2 & H1FY26 Highlights
01 Q2 & H1FY26 Highlights 05 M A N A G E M E N T C O M M E N TA R Y 06 Q U A R T E R LY O P E R AT I O N A L M E T R I C S 07 S U M M A R Y O F P R O F I T A N D LO S S S TAT E M E N T 08 SUMMARY OF BAL ANCE SHEET 09 S U M M A R Y O F C A S H F LO W S TAT E M E N T
Slide 5: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, “In Q2FY26, NGL Fine-Chem Limited witnessed The Company’s capital expenditure programme a steady recovery in demand across its product remains on schedule, with project completion portfolio. This improvement was broad-based, targeted for Q4FY26 and commission
Slide 6: Quarterly Operational Metrics
Quarterly Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q2FY25 Q1FY26 Q2FY26 PARTICULARS Q2FY25 Q1FY26 Q2FY26 ANIMAL API 94% 92% 90% TOP 3 PRODUCTS 38% 30% 32% HUMAN API 3% 4% 4% TOP 5 PRODUCTS 51% 42% 46% INTERMEDIATES 2% 3% 5% TOP 10 PRODUCTS 72% 63% 69% FORMULATIONS
Slide 7: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ IN CRORES PARTICUL ARS Q2FY25 Q1FY26 Q2FY26 Q-o-Q Y-o-Y H1FY25 H1FY26 Y-o-Y REVENUE FROM OPERATIONS 93.48 104.19 120.26 15.43% 28.64% 184.24 224.44 21.82% OTHER INCOME 5.12 6.35 2.05 67.69% -59.86% 11.00 8.41 -23.58% TOTAL INCOME 98.60 110.54 122.31 10.65% 24.0
Slide 8: Summary of Balance Sheet
Summary of Balance Sheet ₹ IN CRORES PARTICUL ARS FY25 H1FY26 SHAREHOLDERS FUND 282.43 300.20 NON CURRENT LIABILITIES 31.99 43.41 LONG TERM BORROWINGS 25.34 35.74 CURRENT LIABILITIES 118.97 140.51 SHORT TERM BORROWINGS 47.82 52.47 TOTAL EQUITY AND LIABILITIES 433.39 484.12 NON CURRENT ASSETS 198.01
Slide 9: Summary of Cash Flow Statement
Summary of Cash Flow Statement ₹ IN CRORES PARTICUL ARS FY25 H1FY26 CASH FLOW FROM OPERATING ACTIVITIES 35.82 16.77 CASH FLOW FROM INVESTING ACTIVITIES (34.55) (14.37) CASH FLOW FROM FINANCING ACTIVITIES (1.08) (1.08) NET CASH FLOW 0.19 1.32 CASH AT THE BEGINNING OF YEAR 0.40 0.58 CASH AT THE END OF
Slide 10: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 11 L E A D I N G A N I M A L H E A LT H C O M PA N Y 12 LEADERSHIP IN VETERINARY API SEGMENT 13 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA B I L I T I E S 14 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 11: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 37 APIs (35 Veterinary • Market leadership in • 3 state of the art • Strong presence • ~404 customers APIs, 2 Human
Slide 12: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT (₹ IN CRORES) 12% CAGR CONCENTRATION (OF SALES FY25) backward integrated facilities leading to cost competitiveness FY25 327 CUSTOMER PRODUCT F
Slide 13: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 19,000 m 2 168 kl 253 kl AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are ca
Slide 14: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSION • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSION AT TARAPUR • Capacity expansion with su
Slide 15: Historical Financial Performance
03 Historical Financial Performance 16 ROBUST FINANCIAL PERFORMANCE
Slide 16: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ IN CRORES) (₹ IN CRORES) (₹ IN CRORES) FY25 368 FY25 34 FY25 21 FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 0 50 100 150 200 250 300 350 400 0 10 20 30 40 50 60 70 80 90 0 10 20 30 40 50 60 GRO
Slide 17: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NGL FINE-CHEM TIL ADVISORS PRIVATE LIMITED LIMITED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 301, E-square, Subhash Road, Vile Parle (East), Mumbai - 400057, M